0.3423
1.85%
0.0076
Fibrogen Inc stock is traded at $0.3423, with a volume of 752.52K.
It is up +1.85% in the last 24 hours and down -12.92% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
See More
Previous Close:
$0.3347
Open:
$0.3526
24h Volume:
752.52K
Relative Volume:
0.62
Market Cap:
$33.58M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-0.101
EPS:
-3.39
Net Cash Flow:
$-317.54M
1W Performance:
+0.68%
1M Performance:
-12.92%
6M Performance:
-71.59%
1Y Performance:
-40.25%
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
FGEN | 0.3423 | 33.58M | 147.75M | -284.23M | -317.54M | -3.39 |
VRTX | 467.20 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.66 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.32 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.33 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jun-26-23 | Downgrade | Stifel | Buy → Hold |
Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Jun-02-23 | Upgrade | Stifel | Hold → Buy |
Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
Jul-16-21 | Downgrade | Stifel | Buy → Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
Feb-01-21 | Initiated | H.C. Wainwright | Buy |
Oct-26-20 | Initiated | Raymond James | Underperform |
Jul-10-20 | Resumed | Stifel | Buy |
May-01-20 | Initiated | Cowen | Market Perform |
Apr-27-20 | Initiated | BofA/Merrill | Neutral |
May-29-19 | Resumed | Goldman | Neutral |
May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-12-19 | Initiated | Piper Jaffray | Neutral |
Feb-11-19 | Resumed | Stifel | Buy |
Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
Aug-08-17 | Reiterated | Leerink Partners | Outperform |
Aug-08-17 | Reiterated | Stifel | Buy |
Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
Jul-11-17 | Initiated | Jefferies | Buy |
Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-21-16 | Initiated | Credit Suisse | Neutral |
Dec-04-15 | Initiated | Citigroup | Buy |
Sep-23-15 | Initiated | Lake Street | Hold |
Jul-29-15 | Initiated | Citigroup | Buy |
Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN) - Defense World
ARMISTICE CAPITAL, LLC Reduces Stake in FibroGen Inc - GuruFocus.com
FibroGen Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com India
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: FibroGen reports strong Q3 sales, advances in oncology pipeline - Investing.com UK
FibroGen: Q3 Earnings Snapshot - mySA
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - MSN
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions - Yahoo Finance
FibroGen Reports Strong Q3 Growth and Future Plans - TipRanks
FibroGen Inc earnings beat by $0.14, revenue topped estimates - Investing.com Australia
FibroGen Inc (FGEN) Q3 2024 Earnings: Revenue Surges to $46.3M, EPS at $(0.17), Exceeding Estimates - GuruFocus.com
FibroGen Reports Third Quarter 2024 Financial Results - GlobeNewswire
FibroGen Q3 Revenue Surges 15% as China Sales Soar; Narrows Net Loss by 73% | FGEN Stock News - StockTitan
FibroGen Inc (FGEN) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewswire
Metrics That Matter About FibroGen Inc (NASDAQ: FGEN) - Stocks Register
FGEN stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding - Simply Wall St
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
FGEN stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com - Defense World
The growth track for FibroGen Inc (FGEN) has changed recently - SETE News
Should investors be concerned about FibroGen Inc (FGEN)? - US Post News
Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Market Watch: FibroGen Inc (FGEN)’s Noteworthy Gain, Closing at 0.36 - The Dwinnex
FibroGen Hits New 52-week High, What's Fuelling The Stock? - RTTNews
Pulmonary Fibrosis Drug Market Size & Analysis By 2024 -2034 -Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., – IndiaPolitics.com - IndiaPolitics.com
Sei Investments Co. Purchases 41,442 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Financial Review: FibroGen (NASDAQ:FGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) - Defense World
FibroGen's US$6.2m Market Cap Fall Books Insider Losses - Simply Wall St
FibroGen Inc [FGEN] Chief Medical Officer makes an insider acquire of 22,123 shares worth 25,884. - Knox Daily
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts - Yahoo Finance
Investors in cash trouble should check out FibroGen Inc (FGEN) - SETE News
FGEN stock touches 52-week low at $0.33 amid market challenges By Investing.com - Investing.com South Africa
FGEN stock touches 52-week low at $0.33 amid market challenges - Investing.com Australia
A year in review: FibroGen Inc (FGEN)’s performance in the last year - US Post News
Trading Day Triumph: FibroGen Inc (FGEN) Ends at 0.37, a -8.07 Surge/Plunge - The Dwinnex
FibroGen Inc Inc. (FGEN) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Investing in FibroGen Inc (FGEN): What You Must Know - Knox Daily
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
FibroGen will pay $10M to exit HQ lease in SF’s Mission Bay - The Real Deal
FibroGen Suit Alleging Disclosure Failures Tossed In Del. - Law360
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Wettig Thane | CEO |
Mar 07 '24 |
Buy |
1.91 |
50,000 |
95,470 |
470,178 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):